From: Childhood Hodgkin Lymphoma Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 7. Treatment Approaches for Patients With Intermediate-Risk Hodgkin Lymphoma
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival (No. of Years of Follow-up) | Survival (No. of Years of Follow-up) |
|---|---|---|---|---|---|
| COPP/ABV (6) [20] | IFRT (21) | CS I/IIb, CS IIB, CS III | 103 | 84% (10)c | 100% (3) |
| None | 122 | 78% (10)c | |||
| OEPA/OPPA (2) + COPP (2) [21] | IFRT (20–35) | IIEA, IIB, IIIA | 212 | 92% (5) | N/A |
| OEPA/OPPA (2) + COPDAC (2) [19] | IFRT (20–35) | IE, IIB, IIEA, IIIA | 139 | 88.3% (5) | 98.5% (5) |
| ABVE-PC (3–5) [18] | IFRT (21) | IIA/IIIA, if bulky disease | 53 | 84% (5) | 95% (5) |
| ABVE-PC: RER/CR [17] | IFRT (21) | IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease | 380 | 87.9% (4) | 98.8% (4) |
| ABVE-PC: RER/CR [17] | None | IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease | 382 | 84.3% (4) | 98.8% (4) |
| ABVE-PC: SER: +DECA [17] | IFRT (21) | IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease | 153 | 79.3% (4) | 96.5% (4) |
| ABVE-PC: SER: -DECA [17] | IFRT (21) | 151 | 75.2% (4) | 94.3% (4) |
CR = complete response; CS = clinical stage; E = extralymphatic; IFRT = involved-field radiation therapy; N/A = not applicable; RER = rapid early response; SER = slow early response.
aRefer to Table 5 for more information about the chemotherapy regimens.
bWith adverse disease features, defined as one or more of the following: hilar adenopathy, involvement of more than four nodal regions; mediastinal tumor with diameter equal to or larger than one-third of the chest diameter, and node or nodal aggregate with a diameter larger than 10 cm.
cResults from as-treated analysis.